Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Barcelona, Spain – Sunday 31 August 2014: Renal denervation reduces recurrent atrial fibrillation (AF) when performed with pulmonary vein isolation ablation in patients with AF and hypertension, according to research presented at ESC Congress today by Dr Alexander Romanov from the Russian Federation.
Dr Romanov said: “The prevalence of AF ranges from 1.5 to 2% in developed countries. This arrhythmia is associated with increased mortality, a five-fold risk of stroke and a 3-fold incidence of congestive heart failure. The vast majority of patients with AF also have arterial hypertension.” (1)
He added: “Up to 10% of patients with arterial hypertension are resistant to modern drug treatment and have so-called resistant hypertension, which is associated with an increased risk of cardiovascular events.” (2)
Renal sympathetic denervation (RD) is a new method that may be effective for controlling resistant hypertension by reducing the hyperactivity of the renal sympathetic nerve. In addition to its anti-hypertensive effects, RD may also exert antiarrhythmic effects, with reports suggesting a potential role for both AF and ventricular tachyarrhythmias. On the other hand, hypertension is an established risk factor for AF, and many cases of apparently “lone” AF (3) can be attributed to latent hypertension. Pulmonary vein isolation (PVI) is a treatment for patients with AF. This catheter ablation technique uses radiofrequency energy to destroy tissue on the veins that is generating extra electrical signals and causing AF.The aim of the present study was to assess the impact of adding RD as an adjunct to PVI in patients with AF and moderate or severe resistant hypertension (4) on AF recurrences and blood pressure changes.The data for this analysis were obtained from two prospective randomised and double-blind studies. The analysis included 80 patients with a history of symptomatic drug refractory paroxysmal and persistent AF and moderate/severe resistant hypertension who underwent PVI and RD (figure 1) compared to PVI only.The researchers found that RD reduced the likelihood of AF when performed with PVI in hypertensive patients. At 12 months follow up, 63% of the patients who had PVI and RD were AF-free compared to 41% of patients in the PVI only group.The benefit was most dramatic in patients with severe drug resistant hypertension and those with persistent AF, although non-significant trends were also seen in patients with moderate hypertension and those with paroxysmal AF. Dr Romanov said: “We could speculate that the limited number of patients enrolled did not allow this trend to reach statistical significance. The use of RD in moderate hypertension as well as the effect on paroxysmal AF deserves further investigation.”RD delivered significant reductions in systolic and diastolic blood pressure. Dr Romanov said: “These results are compatible with those reported by previous trials in severe and moderate resistant hypertension. Moreover, in our study we used high frequency stimulation (5) for confirming the acute effect of RD. We believe this is a critical measure of success of this procedure.”
He concluded: “We found that the addition of RD to PVI may be beneficial in patients with severe resistant hypertension and/or persistent AF. These results confirm our earlier findings but in a larger and more diverse cohort of patients. Additional and larger trials are needed to validate our results, and to assess the effects of combined treatment on maintenance of sinus rhythm and blood pressure control beyond one year.”
Figure 1A. Angiography of the left renal artery; B. Renal ablation with the ablation catheter; C. Three-dimensional reconstructions with sites of radiofrequency ablation represented in red.
(1) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal. 2012;33:2719–2747.(2) 2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal. 2013;34 (28):2159–2219.(3) Lone AF is the term given to AF when there are no clinical or echocardiographic findings of underlying cardiovascular or pulmonary disease and the cause of AF is unknown.(4) Moderate and severe resistant hypertension were defined as office based blood pressure of ≥140/90 mmHg and ≥160/100 mmHg, respectively.(5) High frequency stimulation is a method for performing electrical stimulation near the renal artery ostium. Rectangular electrical stimuli were delivered at the ostium of the targeted renal artery at a frequency of 20 Hz, with an amplitude of 15 V and pulse duration of 10 ms for 10 seconds. Renal sympathetic denervation was considered to have been achieved when the sudden increase of blood pressure (>15 mmHg from invasive arterial monitoring) was eliminated in the presence of HFS.
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2014The ESC Congress is currently the world's largest international congress in cardiovascular medicine. The spotlight of this year's event is “innovation and the heart”. ESC Congress 2014 takes place from 30 August to 3 September at the Fira Gran Via in Barcelona, Spain. For more information on ESC Congress 2014 contact the ESC Press Office.To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2014. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
© 2017 European Society of Cardiology. All rights reserved